Advanced prostatic carcinoma: Early versus late endocrine therapy

J. M. Kozlowski*, W. J. Ellis, J. T. Grayhack

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

114 Scopus citations


Hormonal therapy has been the mainstay of treatment for advanced prostatic carcinoma since 1941. The first and second Veterans Administration trials cast doubt on the efficacy and advisability of early androgen deprivation. However, recent experimental and clinical studies, including a reanalysis of the VACURG data, provide a strong endorsement for early androgen ablation. A detailed risk-benefit analysis also supports this view. To affect long-term survival significantly, early hormonal therapy must be combined with novel systemic treatments effective against hormone-resistant tumor cells.

Original languageEnglish (US)
Pages (from-to)15-24
Number of pages10
JournalUrologic Clinics of North America
Issue number1
StatePublished - Jan 1 1991

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Advanced prostatic carcinoma: Early versus late endocrine therapy'. Together they form a unique fingerprint.

Cite this